Form 4: Indivior Director Juliet Thompson Receives RSU Grant

Indivior Pharmaceuticals director Juliet Thompson was granted 3,722 Restricted Stock Units, increasing her beneficial ownership.

Summary

• Juliet Thompson, a Director of Indivior Pharmaceuticals, Inc. (INDV), acquired 3,722 shares of common stock.
• The acquisition occurred on January 26, 2026, and was a grant of Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of Indivior's common stock.
• The RSUs vest on the day immediately preceding the first annual meeting of stockholders following the grant date, contingent on Ms. Thompson's continued service.
• Following this transaction, Ms. Thompson directly beneficially owns 7,572 shares of common stock.
• Additionally, 5,775 shares are indirectly beneficially owned by her spouse.

Sentiment

Score: 7

Explanation: The filing reports a standard, routine compensation event for a director, which is generally viewed as a neutral to slightly positive development as it aligns management interests with shareholders. It does not indicate any significant operational or financial changes for the company.

Positives

• The grant of Restricted Stock Units aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• Increased beneficial ownership by a director can signal confidence in the company's future prospects.

Future Outlook

The granted Restricted Stock Units are subject to future vesting, which will occur on the day immediately preceding the first annual meeting of the Issuer's stockholders following the grant date, provided the Reporting Person continues her service to the Issuer.

Industry Context

The grant of Restricted Stock Units to a director is a common and standard practice in the pharmaceutical and broader corporate sectors for executive and director compensation, aiming to align leadership's long-term interests with shareholder value.

Comparison to Industry Standards

• Granting equity-based compensation like RSUs to non-executive directors is a widely adopted practice across industries, including pharmaceuticals, to attract and retain talent and ensure alignment with shareholder interests.
• The structure of vesting contingent on continued service is typical for such grants, comparable to practices at companies like Pfizer, Johnson & Johnson, or Merck, which frequently use similar equity incentives for their board members.

Corporate Governance

Related Party Transactions

• Juliet Thompson's spouse indirectly beneficially owns 5,775 shares of Indivior common stock.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value, potentially leading to more shareholder-centric decision-making.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The Restricted Stock Units will vest on the day immediately preceding the date of the first annual meeting of Indivior's stockholders following the grant date, subject to continued service.

Key Dates

Recommendation

This Form 4 reports a routine grant of Restricted Stock Units to a director, which is a standard compensation practice and does not provide new information to alter an investment thesis. It is not indicative of fundamental changes in the company's operations or financial outlook that would warrant a change in investment recommendation.

Keywords

Indivior Pharmaceuticals, INDV, Form 4, Restricted Stock Units, RSU, Director Compensation, Insider Transaction, Stock Grant